Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus carboplatin/taxane induction followed by pembrolizumab maintenance with or without olaparib in first-line metastatic squamous NSCLC
2018-004721-88Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pulmonary squamous cell carcinoma comparing Maintenance pembrolizumab + olaparib with Maintenance pembrolizumab + placebo (2 arms). Primary endpoint: Progression-free survival. Started Apr 2019; status: active.
02
Drugs
pembrolizumabolaparib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2018-004721-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004721-88.